Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arno Therapeutics has entered into worldwide, exclusive license agreements with the Ohio State University or OSU for the rights to commercially develop novel, orally available, targeted therapies for cancer.
Subscribe to our email newsletter
Under the terms of the agreements, Arno has acquired the rights to several small molecules for the treatment of cancer, including OSU-03012 (NSC D728209) and OSU-HDAC42 (NSC D736012). Arno will pay development based milestones and royalties based on sales of the licensed products.
Scott Fields, president and chief medical officer of Arno, said: “We look forward to moving these molecules into the clinic and to hopefully bringing their benefits to patients who need them as soon as possible.”